New Study Shows How mRNA Vaccines Could Transform Cancer Treatment

InnovationHealthcareNew Study Shows How mRNA Vaccines Could Transform Cancer TreatmentByOmer Awan,Senior Contributor.Forbes contributors publish independent expert analyses and insights. Dr. Omer Awan is a practicing physician who covers public health.Follow AuthorJun 02, 2026, 10:30pm EDT--:-- / --:--This voice experience is generated by AI. Learn more.This voice experience is generated by AI. Learn more.Malignant melanoma (cancer of the skin or mucous membranes), developed at the expense of melanocytes (melanocytic tumor). (Photo by: CAVALLINI JAMES/BSIP/Universal Images Group via Getty Images)BSIP/Universal Images Group via Getty ImagesNearly 70% of patients who received a mRNA vaccine in addition to immunotherapy were cancer free after five years from melanoma, compared to 49% of patients that just received immunotherapy, according to a new study published in the Journal of Clinical Oncology. Furthermore, 92% of patients who received the combination therapy were alive at five years, compared to just 71% who used immunotherapy alone.Melanoma is a deadly skin cancer that is difficult to treat if not detected early, and it usually recurs in about half of patients that have been treated within the first five years. How It Works?mRNA vaccines are the same technology that was used in Operation Warp Speed to develop the COVID-19 vaccines responsible for saving millions of lives in America. The mRNA vaccine used in the trial is designed to teach the immune system to recognize a patient’s unique tumor. Scientists sequence a patient’s tumor and identify mutations that are specific to that cancer. Researchers then select abnormal proteins found only in tumor cells, and encode them into an mRNA vaccine. When the vaccine is injected into the body, the body’s cells temporarily produce these proteins, allowing the immune system to learn what the cancer looks like and mount a targeted attack.In this way, the approach is personalized and every patient receives a different mRNA v...